LYEL vs TGTX

For growth investors, TG Therapeutics, Inc.

(TGTX) is the stronger pick with 87. 3% revenue growth year-over-year, versus -41. 0% for Lyell Immunopharma, Inc. (LYEL). TG Therapeutics, Inc. (TGTX) offers the better valuation at 15. 5x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate TG Therapeutics, Inc. (TGTX) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, TG Therapeutics, Inc.

(TGTX) delivered a total return of +7. 0%, compared to -94. 1% for Lyell Immunopharma, Inc. (LYEL). Over 10 years, the gap is even starker: TGTX returned +434. 4% versus LYEL's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TG Therapeutics, Inc.

(TGTX) is the lower-risk stock at 0. 84β versus Lyell Immunopharma, Inc. 's 1. 83β — meaning LYEL is approximately 119% more volatile than TGTX relative to the S&P 500. On balance sheet safety, Lyell Immunopharma, Inc. (LYEL) carries a lower debt/equity ratio of 17% versus 40% for TG Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TG Therapeutics, Inc.

(TGTX) is pulling ahead at 87. 3% versus -41. 0% for Lyell Immunopharma, Inc. (LYEL). On earnings-per-share growth, the picture is similar: TG Therapeutics, Inc. grew EPS 1747% year-over-year, compared to -1126. 0% for Lyell Immunopharma, Inc.. Over a 3-year CAGR, TGTX leads at 504. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TG Therapeutics, Inc.

(TGTX) is the more profitable company, earning 72. 6% net margin versus -7623. 6% for Lyell Immunopharma, Inc. — meaning it keeps 72. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TGTX leads at 20. 0% versus -5660. 4% for LYEL. At the gross margin level — before operating expenses — TGTX leads at 83. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LYEL: 129.

3% to $46. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TG Therapeutics, Inc.

(TGTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84), +434. 4% 10Y return). Lyell Immunopharma, Inc. (LYEL) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TGTX: +434. 4%, LYEL: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LYEL is a small-cap quality compounder stock; TGTX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.